World News: 14:00 GMT Wednesday 17th April 2019. [Immuron Limited via Globe Newswire via SPi World News]
MELBOURNE, Australia, April 17, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced the appointment of Dr. Gary S. Jacob, CEO of Immuron Ltd. to the Board of Directors as a Director.
Dr. Jacob was appointed Chief Executive Officer of Immuron Ltd. on 19 November 2018 and this appointment to the Board is as envisaged in his employment agreement.
The material terms of Dr. Jacob’s employment agreement are set out below as required by Listing Rule 3.16.4.
For more information visit: .
Gary S. Jacob, Ph.D.
Chief Executive Officer
Ph: +61 (0)3 9824 5254
AUS INVESTOR RELATIONS:
Ph: +61 (0)4 1203 6231
USA INVESTOR RELATIONS:
Dave Gentry - CEO
RedChip Companies, Inc.
US Ph: +1 (407) 491 4498
Globe Newswire: 14:00 GMT Wednesday 17th April 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.